Data from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy

• DOI: 10.1158/1078-0432.c.6533077.v1
• Publication Date: 2023-04-01T04:08:20Z
• Authors: Younes Belkouchi; Hugues Talbot; Nathalie Lassau; Littisha Lawrance; Siham Farhane; Rahma Feki-Mkaouar; Joya Hadchiti; Lama Dawi; Julien Vibert; Paul-Henry Cournède; Clara Cousteix; Camille Mazza; Michele Kind; Antoine Italiano; Aurelien Marabelle; Samy Ammari; Stephane Champiat
• Keywords: Log-rank test; Univariate analysis; Univariate; Progression-free survival

<div>AbstractPurpose:<p>The objective of the study is to propose immunotherapy progression decision (iPD) score, a practical tool based on patient features that are available at first evaluation treatment, help oncologists decide whether continue treatment or switch rapidly another therapeutic line when facing progressive disease evaluation.</p>Experimental Design:<p>This retrospective included 107 patients with according RECIST 1.1. Clinical, radiological, and biological data baseline were analyzed. An external validation set consisting 31 similar characteristics was used for score.</p>Results:<p>Variables analyzed in univariate study. The iPD score constructed using only independent variables, each considered as worsening factor survival patients. stratified three groups: good prognosis (GP), poor (PP), critical (CP). Each group showed significantly different survivals (GP: 11.4, PP: 4.4, CP: 2.3 months median overall survival, <i>P</i> < 0.001, log-rank test). Moreover, able detect pseudoprogressors better than other scores. On set, CP had worse PP GP (<i>P</i> 0.05, test).</p>Conclusions:<p>The provides new evaluation, computable progression, should be continued (for group), immediately changed groups. Further larger cohorts needed prove its efficacy clinical practice.</p></div>